Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity. NVO is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Based on their value, growth, and momentum characteristics ... Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full ...

Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...

Novo Nordisk markets medications that target diabetes, obesity, growth disorders, hemophilia, and hormone replacement. All of Vertex's revenue (for now, at least) stems from its therapies that ...

The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to ...

for two ailments specific to Hemophilia A and growth hormone disorder. “We need to build our employees here so that we can meet that growing patient demand in those areas,” said Gariepy. The West ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...